4
Total investments
2
Early stage
0
Mid stage
1
Late stage
9y
Years active
Portfolio
3 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Board Member
May 2020
Find Therapeutics is clinical-stage biopharmaceutical company dedicated to the development of next generation therapies to treat inflammatory autoimmune diseases. The company was launched in 2020 and is supported with investments from CTI Life Sciences, adMare BioInnovations, Domain Therapeutics and Investissment Québec and an exclusive license from SATT-Conectus and the University of Strasbourg on a technology and related know-how.
Board Observer
Feb 2017
Visterra is a clinical stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. Our proprietary technology platform enables the design and engineering of precision antibody-based product candidates that specifically bind to, and modulate, key disease targets. Applying this technology to disease targets that are not adequately addressed by traditional therapeutic approaches, we are developing a robust pipeline of novel therapies for patients with unmet needs. Our most advanced program is in Phase 2 clinical development.
In addition, Visterra has established a number of partnerships to progress novel antibodies engineered to treat significant diseases with limited treatment options.
I
Board Observer
Jan 2017
ILKOS THERAPEUTICS Inc. is a research company based out of Laval, Quebec, Canada.
Experience · 9 entries
All (9)
Investments (4)
Board (4)
2020
F
Find Therapeutics
Board Member
May 2020
Board Member
May 2020
Find Therapeutics is clinical-stage biopharmaceutical company dedicated to the development of next generation therapies to treat inflammatory autoimmune diseases. The company was launched in 2020 and is supported with investments from CTI Life Sciences, adMare BioInnovations, Domain Therapeutics and Investissment Québec and an exclusive license from SATT-Conectus and the University of Strasbourg on a technology and related know-how.
2017
Board Observer
Feb 2017
Visterra is a clinical stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. Our proprietary technology platform enables the design and engineering of precision antibody-based product candidates that specifically bind to, and modulate, key disease targets. Applying this technology to disease targets that are not adequately addressed by traditional therapeutic approaches, we are developing a robust pipeline of novel therapies for patients with unmet needs. Our most advanced program is in Phase 2 clinical development.
In addition, Visterra has established a number of partnerships to progress novel antibodies engineered to treat significant diseases with limited treatment options.
I
Board Observer
Jan 2017
ILKOS THERAPEUTICS Inc. is a research company based out of Laval, Quebec, Canada.
C
CTI LSF II
Partner
Jan 2017
Show all 9 entries ↓
Investment activity
2017–2020 · 4 investments
Recent (last 2 years)Earlier